Uchida A, Isobe Y, Asano J, Uemura Y, Hoshikawa M, Takagi M, Miura I. Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements. Haematologica 2019; 104(7):1417-1421; https://doi.org/10.3324/haematol.2018.204958.